BBA
RNAC icon

Baker Bros. Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Baker Bros. Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,125
Closed -$1.24M – 111
2018
Q2 		$1.24M Hold
3,125
– – 0.01% 103
2018
Q1 		$955K Sell
3,125
-6,332
-67% -$1.8M 0.01% 101
2017
Q4 		$2.78M Sell
9,457
-203
-2% -$88.7K 0.02% 92
2017
Q3 		$5.29M Hold
9,660
– – 0.04% 77
2017
Q2 		$5.76M Buy
9,660
+3,803
+65% +$1.68M 0.05% 63
2017
Q1 		$2.52M Hold
5,857
– – 0.02% 84
2016
Q4 		$3.01M Sell
5,857
-108
-2% -$63.1K 0.03% 77
2016
Q3 		$2.55M Hold
5,965
– – 0.02% 88
2016
Q2 		$2.5M Buy
+5,965
New +$2.51M 0.03% 90

Other funds holding RNAC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $46.4M AUM 13.94% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baker Bros. Advisors's RNAC Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Cartesian Therapeutics (RNAC) in Q3 2018, closing a stake of 3,125 shares — an estimated $1.24M sold.

Baker Bros. Advisors first reported a position in RNAC in Q2 2016 and held it in 9 quarters. The position peaked at $5.76M in Q2 2017. 65 funds tracked by Wall St. Rank hold RNAC as of Q3 2018.

  • Baker Bros. Advisors reported no remaining Cartesian Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Baker Bros. Advisors sold 3,125 Cartesian Therapeutics shares in Q3 2018, an estimated $1.24M.
  • Baker Bros. Advisors first reported a position in Cartesian Therapeutics in Q2 2016 and held it in 9 quarters.
  • Baker Bros. Advisors's Cartesian Therapeutics position peaked at $5.76M in Q2 2017.
  • 65 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.